Search results
Jun 27, 2024 · Celsius’ lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD. TREM1 has been identified as a key disease driver gene in IBD, where it is expressed on inflammatory monocytes and neutrophils.
Jun 27, 2024 · NORTH CHICAGO, Ill., June 27, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody ...
Jun 13, 2024 · FutureGen has utilized STEP to develop CLDN18.2 antibody-dependent cellular cytotoxicity (ADCC) enhanced antibody (FG-M108), a potential best-in-class product with excellent efficacy and superior safety in the first-line treatment of advanced G/GEJ and pancreatic cancer, currently in Phase 3.
Jun 20, 2024 · How AbbVie is bringing antiviral expertise to the COVID-19 battle. At the first sign of the pandemic, AbbVie began evaluating ways to help, including accelerating discovery efforts and external collaborations.
Jun 28, 2024 · June 28, 2024. The strategic move expands AbbVie’s footprint in the treatment of inflammatory diseases. Credit: Kmpzzz / Shutterstock. AbbVie has acquired biotechnology company Celsius Therapeutics in a deal valued at $250m in cash. Celsius focuses on developing new treatments for inflammatory diseases.
3 days ago · AbbVie also cut its second-quarter adjusted profit to $2.53 to $2.57 per share from $3.05 to $3.09. The company said it incurred $937 million in expenses during the quarter related to ...
Jun 25, 2024 · AbbVie has announced positive data for its antibody-drug conjugate (ADC) therapies, Teliso-V, ABBV-400 and ABBV-706, from Phase I and II trials in solid tumour indications.
